Shares of Antares Pharma Inc. (NASDAQ:ATRS) traded at a new 52-week high today of $5.15. This new high was reached on above average trading volume as 136.2 million shares traded hands, while the average 30-day volume is approximately 924,000 shares.
Based on a current price of $4.00, Antares Pharma Inc. is currently 1.2% above its average consensus analyst price target of $3.95.
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company’s products include OTREXUP, Elestrin, Gelnique, Makena, and others.
In the past 52 weeks, shares of Antares Pharma Inc. have traded between the current low of $0.70 and a high of $4.63 and is now at $4.00.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer